Trevi Therapeutics
Tracked across 1 events · 11 articles · First seen Apr 16, 2026 · Last active Apr 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Trevi Therapeutics announced the pricing of its underwritten public offering of 11,600,000 shares of its common stock at $13.00 per share, raising approximately $150 million. This offering is expected to provide capital for the company's operations and development of Haduvio.
Apr 16, 2026 · 11 articles
100
Trevi Therapeutics priced underwritten public offering of common stockTrevi Therapeutics Prices...
80
Trevi Therapeutics granted underwriters option to purchase additional sharesTrevi Therapeutics Prices...
70
Morgan Stanley acted as joint book-running manager Trevi TherapeuticsTrevi Therapeutics Prices...
70
Leerink Partners acted as joint book-running manager Trevi TherapeuticsTrevi Therapeutics Prices...
70
Cantor Fitzgerald acted as joint book-running manager Trevi TherapeuticsTrevi Therapeutics Prices...
70
Stifel acted as joint book-running manager Trevi TherapeuticsTrevi Therapeutics Prices...
60
Oppenheimer Holdings acted as lead manager Trevi TherapeuticsTrevi Therapeutics Prices...
NEWSDESK
Track Trevi Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard